AI-assisted diagnosis system for autoimmune pancreatitis
Study on AI-assisted Multimodal Diagnosis System of Autoimmune Pancreatitis Based on the Mechanism of Tfh Activation by Intestinal Bacteria and Endosonographic Features
This study is testing a new AI tool that combines ultrasound images and other health markers to see if it can help doctors diagnose autoimmune pancreatitis more accurately.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 180 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06369909 on ClinicalTrials.gov |
What this trial studies
This study focuses on developing an AI-assisted multimodal diagnostic system for autoimmune pancreatitis (AIP) by integrating endoscopic ultrasound (EUS) findings with gut microbiota and T follicular helper cell activation markers. The research aims to improve diagnostic efficiency and accuracy, addressing the complexities of current diagnostic methods for AIP. By utilizing a national multicenter queue and extracting EUS audio-visual features, the study seeks to establish a scoring model that enhances the identification of AIP. The collaboration among multiple research centers aims to validate the role of Klebsiella pneumoniae in AIP pathogenesis.
Who should consider this trial
Good fit: Ideal candidates include patients with pancreatic solid lesions suspected or diagnosed with autoimmune pancreatitis who are willing to participate and meet the inclusion criteria.
Not a fit: Patients who are not suitable for endoscopic examination or cannot understand the study's conditions and objectives may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and efficient diagnosis of autoimmune pancreatitis, improving patient outcomes.
How similar studies have performed: While the integration of AI in diagnostic systems is gaining traction, this specific approach to autoimmune pancreatitis is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * From the beginning of the study to the end of the study, patients with pancreatic solid lesions suspected or diagnosed with AIP were treated at Peking Union Medical College Hospital and related research centers. * The patients themselves and their families understood and were willing to participate in this study, and signed an informed consent form. * The diagnosis of AIP must comply with the criteria of the Chinese Guidelines for the Diagnosis and Treatment of Autoimmune Pancreatitis (2022). Exclusion Criteria: * Individuals who are not suitable for endoscopic examination, including but not limited to: generally poor condition, severe cardiovascular and pulmonary diseases, and difficulty tolerating the examination, coagulation disorders and those who are deemed unsuitable for endoscopic examination by an endoscopist after a face-to-face consultation. * Patients or family members are unable to understand the conditions and objectives of this study.
Where this trial is running
Beijing, Beijing
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Xi Wu, M.D.
- Email: xiwbj@aliyun.com
- Phone: 13683296860
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.